Insider Buying: PhaseBio Pharmaceuticals Inc (PHAS) Director Acquires 4,000 Shares of Stock

Share on StockTwits

PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) Director Clay Thorp bought 4,000 shares of the company’s stock in a transaction on Tuesday, December 4th. The stock was purchased at an average cost of $3.13 per share, for a total transaction of $12,520.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of NASDAQ PHAS opened at $4.09 on Friday. PhaseBio Pharmaceuticals Inc has a 52 week low of $2.55 and a 52 week high of $6.00.

PhaseBio Pharmaceuticals (NASDAQ:PHAS) last issued its quarterly earnings data on Thursday, November 29th. The company reported ($10.45) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($10.23). The firm had revenue of $0.41 million during the quarter. As a group, equities analysts anticipate that PhaseBio Pharmaceuticals Inc will post -12.08 earnings per share for the current year.

Several brokerages have weighed in on PHAS. Needham & Company LLC began coverage on PhaseBio Pharmaceuticals in a research report on Tuesday, November 13th. They issued a “buy” rating and a $18.00 target price on the stock. Stifel Nicolaus began coverage on PhaseBio Pharmaceuticals in a research report on Monday, November 12th. They issued a “buy” rating and a $14.00 target price on the stock. Cowen initiated coverage on PhaseBio Pharmaceuticals in a research report on Monday, November 12th. They issued an “outperform” rating on the stock. Finally, Citigroup initiated coverage on PhaseBio Pharmaceuticals in a report on Monday, November 12th. They set a “buy” rating and a $18.00 price objective on the stock.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/4001090/insider-buying-phasebio-pharmaceuticals-inc-phas-director-acquires-4000-shares-of-stock.html.

About PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery.

Featured Article: Investing in Growth Stocks

Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

LVMH Moet Hennessy Louis Vuitton  Lifted to Hold at Zacks Investment Research
LVMH Moet Hennessy Louis Vuitton Lifted to Hold at Zacks Investment Research
Direct Line Insurance Group  Price Target Cut to GBX 344
Direct Line Insurance Group Price Target Cut to GBX 344
Manx Telecom  Rating Reiterated by Liberum Capital
Manx Telecom Rating Reiterated by Liberum Capital
UBS Group Reaffirms Buy Rating for BP
UBS Group Reaffirms Buy Rating for BP
888 Holdings Public  Rating Reiterated by Peel Hunt
888 Holdings Public Rating Reiterated by Peel Hunt
Peel Hunt Lowers Berkeley Group  to Add
Peel Hunt Lowers Berkeley Group to Add


Leave a Reply

© 2006-2018 Ticker Report